For example, Pax-5 promoted an oncogenic role in specific lymphoproliferative cancers (ex: CLL and DLBCL), whereas in mammary cancers, Pax-5 elicited tumor suppressor features and promoted cellular epithelialization [53,54]. This evidence concerns the gene PAX5 and B-cell chronic lymphocytic leukemia.